Canada has arrived at a moment where its public‑health policies no longer simply contradict one another—they actively undermine each other. In many cities, it is now easier to access hard drugs on the street than it is to buy a legally approved product designed to help adults quit smoking. That reality is not the result of ideology or accident. It is the outcome of two federal policy tracks that have drifted so far apart they now expose a deep incoherence at the heart of Canada’s harm‑reduction strategy.
Over the past decade, governments at both the federal and provincial levels have embraced an expansive model of harm reduction. Supervised consumption sites, safer‑supply programs, and the widespread distribution of drug‑use paraphernalia have become central pillars of national drug policy. The intention behind these measures is understandable: reduce overdoses, keep people alive, and connect them with services. But the practical effect has been something very different. Public drug use has become normalized, visible, and increasingly unregulated. Communities across the country report disorder, safety concerns, and a growing sense that government has lost control of the streets. In many urban centres, it is now easier to obtain taxpayer‑funded opioids or use hard drugs openly in public spaces than it is to access basic smoking‑cessation tools sold legally in most other countries.
This is the backdrop against which the nicotine‑pouch debate now sits, and the contrast is impossible to ignore.
When Health Canada approved Zonnic nicotine pouches in 2023, the logic was straightforward: give adults who smoke another tool to quit. For a brief period, the product was sold in convenience stores and gas stations alongside other nicotine‑replacement therapies such as gum and lozenges. Then, within a year, the federal government reversed course. Ottawa restricted nicotine pouches to pharmacies only, limited flavours to mint and menthol, and justified the move as a youth‑protection measure. The decision created a regulatory environment where the very product approved to help people quit smoking suddenly became harder to access than cigarettes themselves.
The inconsistency is striking. Flavoured nicotine gum and lozenges remain widely available in convenience stores. Cigarettes, far more harmful, are still sold in those same stores. Other nicotine‑replacement therapies continue to use colours, flavours, and packaging identical to what Zonnic was criticized for. Yet Zonnic alone was singled out for restrictions so tight that adults now face more barriers to buying a mint‑flavoured cessation pouch than to witnessing or encountering open drug use in public spaces.
The government’s logic does not hold. If the concern is youth access, why are youth exposed daily to public drug use in parks, transit stations, and downtown cores? If convenience stores cannot be trusted to sell age‑restricted products, why are they still allowed to sell cigarettes, lottery tickets, alcohol in some provinces, and every other nicotine‑replacement therapy on the market? If harm reduction is the guiding principle, why is the product designed to reduce harm treated more harshly than the substances that cause it?
No reasonable person disputes the need to keep nicotine away from minors. But the government’s approach applies this principle selectively. Youth exposure to public drug use has increased dramatically, with little federal urgency to restrict access to the environments where it occurs. Youth can still access cigarettes through the same retail channels now deemed too risky for cessation tools. Other flavoured NRTs remain untouched, despite using the same colours, packaging, and flavour profiles that triggered the crackdown on pouches. The selective enforcement suggests the issue is not youth protection—it is political optics.
The result is a harm‑reduction double standard. Canada’s drug policy is built on the idea that reducing barriers saves lives. Yet when it comes to smoking cessation—a long‑standing public‑health priority—the government has erected new barriers that make quitting harder. Hard drugs have become easier to access than ever, while smoking‑cessation tools have become harder to access than ever. One policy expands access in the name of harm reduction. The other restricts access in the name of harm reduction. Both cannot be true at the same time.
This contradiction sends mixed signals to Canadians. Addiction to illicit drugs is met with open‑access supports. Addiction to cigarettes is met with tightened restrictions on cessation tools. Communities are told to tolerate public drug use but are denied convenient access to products that help people quit smoking. This is not a coherent public‑health strategy. It is a patchwork of political impulses that leaves Canadians caught in the middle.
A more consistent, evidence‑based approach is possible. It would protect youth without restricting adult access to cessation tools. It would align nicotine‑replacement regulations with existing NRT standards. It would recognize that harm reduction must apply to all addictions, not just the politically salient ones. And it would ensure that communities are not collateral damage in drug‑policy experiments.
The goal should be simple: make it easier to quit harmful substances than to continue using them. Right now, Canada has that equation backwards.
